FERAHEME 30 MG — DIN 02377217
IRON (FERUMOXYTOL) : 30 MG · AMAG PHARMACEUTICALS INC · SOLUTION · wholesale supply in Canada
Health Canada status: CANCELLED POST MARKET
What is FERAHEME?
FERAHEME 30 MG contains IRON (FERUMOXYTOL) : 30 MG. It is listed in the Health Canada Drug Product Database under DIN 02377217, held by AMAG PHARMACEUTICALS INC, supplied as SOLUTION for INTRAVENOUS administration. Health Canada currently lists it as cancelled post market, status dated 26-Sep-2016. This Drug Identification Number is no longer authorized for sale in Canada, so Nexara does not supply it. The record is kept here because buyers still meet the number on old formularies, purchase orders and tender documents; Nexara can help identify an authorized alternative.
Is there a generic Iron, Parenteral Preparations in Canada, and who makes it?
Every market authorization holder with a Canadian DIN for this molecule, and how many of their listings Health Canada currently shows as marketed.
10 holders have a Canadian DIN containing Iron, Parenteral Preparations, across 10 DINs, of which 5 are currently marketed. Marketed count is the number that matters: an approval that is not marketed cannot be bought.
| Market authorization holder | DINs | Marketed | Brand names | Position |
|---|---|---|---|---|
| FRESENIUS MEDICAL CARE CAN INC | 1 | 1 | VENOFER | Sourceable in Canada |
| Pfizer Canada Ulc | 1 | 1 | MONOFERRIC | Sourceable in Canada |
| PHARMASCIENCE INC | 1 | 1 | PMS-IRON SUCROSE | Sourceable in Canada |
| SANOFI-AVENTIS CANADA INC | 1 | 1 | FERRLECIT | Sourceable in Canada |
| VIFOR (INTERNATIONAL) INC. | 1 | 1 | FERINJECT | Sourceable in Canada |
| AMAG PHARMACEUTICALS INC | 1 | 0 | FERAHEME | No marketed DIN |
| AMERICAN REGENT, INC | 1 | 0 | DEXIRON | No marketed DIN |
| ASTRAZENECA CANADA INC | 1 | 0 | JECTOFER 50 MG/ML | No marketed DIN |
| ROCKWELL MEDICAL INC | 1 | 0 | TRIFERIC AVNU | No marketed DIN |
| SANDOZ CANADA INCORPORATED | 1 | 0 | INFUFER | No marketed DIN |
Health Canada’s Drug Product Database does not flag which listing is the originator and which are subsequent-entry products, so Nexara does not label them here. Interchangeability is determined provincially, not federally — confirm for your province before a formulary switch. Nexara can confirm which of these is actually obtainable, and on what lead time, per order.
How is it supplied and stored?
Pack configuration, storage class and the handling constraints that drive cold-chain planning. One DIN can cover more than one pack size, and the pack — not the DIN — is what gets priced, shipped and invoiced.
| Strength on the label | 30 MG |
|---|---|
| Dosage form | SOLUTION |
| Route | INTRAVENOUS |
Pack detail is kept as a regulatory record. This DIN is no longer authorized for sale in Canada, so Nexara does not quote this pack.
Substance and classification
| Active substance | Iron, Parenteral Preparations |
|---|---|
| ATC code | B03AC |
| AHFS class | 20:04.04 |
| Biosimilar biologic | No |
Health Canada record and identifiers
The regulatory facts straight from the Drug Product Database, plus every identifier form Nexara accepts on a purchase order. A DIN written without its leading zeros is the commonest reason an order line fails to match.
| DIN (8-digit, as used in ordering) | 02377217 |
|---|---|
| DIN (unpadded, as printed on some documents) | 2377217 |
| Brand name | FERAHEME |
| Generic / active ingredient | IRON (FERUMOXYTOL) : 30 MG |
| Market authorization holder | AMAG PHARMACEUTICALS INC |
| Health Canada schedule | Prescription |
| ATC code | B03AC |
| ATC anatomical main group | B — Blood and blood-forming organs |
| ATC therapeutic subgroup | B03AC |
| Current status | CANCELLED POST MARKET |
| Status date | 26-Sep-2016 |
| Original market date | 2012-05-01 00:00:00 |
| Status source | Live Health Canada DPD sync |
Verify on the primary sources
What can be used instead?
Alternatives on every axis a buyer actually considers — the same molecule in another presentation, the same class, an adjacent class, or a fixed-dose combination. Every row is led by the marketed DIN count, because that is what can be bought this week.
1 · Same molecule, other Canadian presentations
5 of 10 Canadian DINs for this molecule are currently marketed. Marketed products are listed first.
| Product | Strength | Form | Holder | Health Canada status | DIN |
|---|---|---|---|---|---|
| FERINJECT | 50 MG | DISPERSION | VIFOR (INTERNATIONAL) INC. | MARKETED | 02546078 |
| FERRLECIT | 12.5 MG | SOLUTION | SANOFI-AVENTIS CANADA INC | MARKETED | 02243333 |
| MONOFERRIC | 100 MG | SOLUTION | Pfizer Canada Ulc | MARKETED | 02477777 |
| PMS-IRON SUCROSE | 20 MG | SOLUTION | PHARMASCIENCE INC | MARKETED | 02502917 |
| VENOFER | 20 MG | SOLUTION | FRESENIUS MEDICAL CARE CAN INC | MARKETED | 02243716 |
| DEXIRON | 50 MG | SOLUTION | AMERICAN REGENT, INC | CANCELLED POST MARKET | 02205963 |
| INFUFER | 50 MG | LIQUID | SANDOZ CANADA INCORPORATED | CANCELLED POST MARKET | 02221780 |
| JECTOFER 50 MG/ML | 100 MG | LIQUID | ASTRAZENECA CANADA INC | CANCELLED POST MARKET | 00001910 |
| TRIFERIC AVNU | 1.5 MG | SOLUTION | ROCKWELL MEDICAL INC | CANCELLED PRE MARKET | 02515334 |
2 · Same class — other molecules in ATC B03AC
| Molecule | Canadian brands | DINs | Marketed | Sourceable |
|---|---|---|---|---|
| Iron, Parenteral Preparations | DEXIRON · FERAHEME · FERINJECT · FERRLECIT · +6 more | 10 | 5 | Yes |
A molecule with zero marketed DINs cannot be sourced domestically, however many approvals it holds — if one of these sits on a formulary or in an older protocol, that is the line to check.
3 · Adjacent classes in ATC B03A
| ATC subgroup | Molecules | DINs | Marketed |
|---|---|---|---|
| B03AE | Iron And Multivitamins · Iron In Other Combinations · Iron, Multivitamins And Minerals · Iron, Vitamin B12 And Folic Acid · Various Combinations | 39 | 2 |
| B03AB | Ferric Maltol · Saccharated Iron Oxide | 2 | 1 |
| B03A | Iron Preparations | 1 | 0 |
| B03AA | Ferrous Ascorbate · Ferrous Fumarate · Ferrous Fumarate, Combinations · Ferrous Gluconate · Ferrous Sulphate · +3 more | 40 | 0 |
| B03AD | Ferrous Fumarate And Folic Acid · Ferrous Sulphate And Folic Acid | 3 | 0 |
Not clinical advice. These tables describe what can be supplied in Canada, not what should be prescribed. Substitution within or across classes is a prescriber and pharmacist decision, and interchangeability is determined provincially.
Can this still be bought in Canada?
No. This Drug Identification Number is cancelled post market in Health Canada's Drug Product Database, so the product is no longer authorized for sale in Canada and Nexara does not supply it. This page is kept as a regulatory record.
If you are looking for a current equivalent, the alternatives above list every product sharing this therapeutic class, with the marketed ones first. Ask us to source an alternative
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address. Patients and unlicensed buyers are routed to a partner pharmacy.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Why is there no price on this page?
Nexara quotes a delivered Canadian price per order, against a verified licence. Foreign list prices are published on incompatible bases and are not a guide to what any buyer can obtain here, so this page shows which markets list the molecule and on what basis, and nothing more.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.